drugset / Trial / NCT00137436
Study Of SU011248 In Combination With Docetaxel (Taxotere) And Prednisone In Patients With Prostate Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a multi-center, open-label, Phase 1/2 study of SU011248 (sunitinib malate, SUTENT) in combination with docetaxel and prednisone for the first-line treatment of metastatic hormone-refractory prostate cancer (mHRPC).
Timeline
- Start
- 2005-10
- Primary completion
- 2008-05
- Completion
- 2010-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | 60 mg/m2 | Intravenous |
| Subject | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |
| Subject | Sunitinib | Small molecule | 12.5 mg | Oral |
| Subject | Sunitinib | Small molecule | 37.5 mg | Oral |
| Subject | Sunitinib | Small molecule | 50 mg | Oral |
| Background | Prednisone | Other / unclassified | 5 mg | Oral |